Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 17, 2026, 9:13 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–11 of 11 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Standard Therapeutic DLI Clear all
Completed Phase 2 Interventional Results available

Bone Marrow Transplantation of Patients in Remission Using Partially Matched Relative Donor

NCT01350245
View directory record Official record
Conditions
Acute Myeloid Leukemia, Myelodysplastic Syndromes, Biphenotypic Leukemia, Acute Lymphocytic Leukemia, Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Plasma Cell Neoplasms, Lymphoma, Hodgkin's Disease, Aplastic Anemia
Interventions
Total Body Irradiation (TBI), Donor Lymphocyte Infusion (DLI), Cyclophosphamide, Mycophenolate Mofetil (MMF), Tacrolimus, Hematopoietic stem cell transplantation (HSCT)
Radiation · Biological · Drug + 1 more
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 15, 2025 · Synced Sep 17, 2026, 9:13 AM EDT
Terminated Not applicable Interventional Results available

AML Therapy With Irradiated Allogeneic Cells

NCT02105116
View directory record Official record
Conditions
Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b), Adult Acute Myeloblastic Leukemia With Maturation (M2), Adult Acute Myeloblastic Leukemia Without Maturation (M1), Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Acute Myelomonocytic Leukemia (M4), Adult Erythroleukemia (M6a), Adult Pure Erythroid Leukemia (M6b), Recurrent Adult Acute Myeloid Leukemia, Untreated Adult Acute Myeloid Leukemia
Interventions
fludarabine phosphate, cytarabine, donor lymphocytes, laboratory biomarker analysis, G-CSF
Drug · Biological · Other
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 23, 2021 · Synced Sep 17, 2026, 9:13 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Safety and Efficacy of Allogeneic HPV-specific T Cells in Adults With Recurrent or Metastatic HPV16+ Cancers

NCT04713046
View directory record Official record
Conditions
HPV 16+ Recurrent or Metastatic Cancer
Interventions
CD8 reduced peripheral blood cells taken from related donors vaccinated against HPV16, Non-myeloablative allogeneic bone marrow transplant from related donors vaccinated against HPV16
Biological
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Sep 17, 2026, 9:13 AM EDT
Completed Phase 1Phase 2 Interventional Results available

CD8 Depleted, Non-engrafting, HLA Mismatched Unrelated Infusion With MDS and Secondary AML

NCT04620681
View directory record Official record
Conditions
Myelodysplastic Syndromes, Secondary Acute Myeloid Leukemia
Interventions
CD8 Depleted, Non-engrafting,HLA mismatched unrelated donor lymphocytes, Standard of Care Chemotherapy
Biological · Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years to 79 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced Sep 17, 2026, 9:13 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Cytokine Induced Memory-like NK Cell Adoptive Therapy for Relapsed AML After Allogeneic Hematopoietic Cell Transplant

NCT03068819
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
CIML NK Cell Infusion, CD3+ T Cell Product Infusion, Leukapheresis
Drug · Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Sep 17, 2026, 9:13 AM EDT
Completed Phase 2 Interventional Results available

Donor Lymphocyte Infusion With Azacitidine to Prevent Hematologic Malignancy Relapse After Stem Cell Transplantation

NCT02458235
View directory record Official record
Conditions
Acute Myelogenous Leukemia, Acute Lymphoid Leukemia, Juvenile Myelomonocytic Leukemia, Myelodysplastic Syndrome
Interventions
azacitidine, donor lymphocyte infusion
Drug · Biological
Lead sponsor
University of California, San Francisco
Other
Eligibility
Up to 29 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 11, 2020 · Synced Sep 17, 2026, 9:13 AM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers

NCT00074490
View directory record Official record
Conditions
Lymphoma, Leukemia, Myeloproliferative Disorders, Multiple Myleoma, Myelodysplastic Syndrome
Interventions
Rituximab, Fludarabine, Etoposide, Doxorubicin, Vincristine, Cyclophosphamide, Peripheral blood stem cell (PBSC) transplantation, T cell donor lymphocyte infusion (DLI) with unmanipulated donor T cells, Prednisone, Allogeneic hematopoietic stem cell transplant (HSCT), Filgrastim, T-Rapa cell Donor Lymphocyte Infusion (DLI)
Drug · Procedure · Genetic
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
11 Years to 90 Years
Enrollment
442 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2017
U.S. locations
2
States / cities
Bethesda, Maryland • Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 30, 2018 · Synced Sep 17, 2026, 9:13 AM EDT
Completed Phase 1 Interventional

Haploidentical Stem Cell Transplant with Prophylactic Natural Killer DLI for Lymphoma, Multiple Myeloma, and CLL

NCT03524235
View directory record Official record
Conditions
Multiple Myeloma, CLL, Chronic Lymphocytic Leukemia, Lymphoma, Hodgkin Lymphoma
Interventions
Total Body Irradiation, Haploidentical Stem Cell Transplantation, CD56-Enriched Donor Lymphocyte Infusion, Bendamustine, Fludarabine, Rituximab
Radiation · Procedure · Biological + 1 more
Lead sponsor
Noah Merin
Other
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 11, 2024 · Synced Sep 17, 2026, 9:13 AM EDT
Completed Phase 1 Interventional

Infusion of Allogeneic CD19-Specific T Cells From Peripheral Blood

NCT01497184
View directory record Official record
Conditions
Leukemia, Lymphoma
Interventions
HSCT, DLI
Procedure · Genetic
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
1 Year to 65 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 12, 2025 · Synced Sep 17, 2026, 9:13 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Donor Lymphocyte Infusion (DLI) of T-cells Genetically Modified With iCasp9 Suicide Gene

NCT01875237
View directory record Official record
Conditions
Leukemia, Myeloma, Myeloproliferative Diseases
Interventions
Fludarabine, Melphalan, Alemtuzumab, Stem Cell infusion, Tacrolimus, Mini Methotrexate, G-CSF, Donor Lymphocyte Infusion (DLI), AP1903, Methylprednisolone, Questionnaire
Drug · Procedure · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 65 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 15, 2019 · Synced Sep 17, 2026, 9:13 AM EDT
Not yet recruiting Phase 1 Interventional

Prophylactic and Therapeutic DLI-X for Leukemia Relapse After HCT

NCT07254793
View directory record Official record
Conditions
Acute Lymphoid Leukemia, Acute Myeloid Leukemia, Acute Undifferentiated Leukemia (AUL), Myelodysplastic Syndrome, Chronic Myeloid Leukemia, Non-Hodgkin Lymphoma
Interventions
Exercise Mobilized Prophylactic DLI, Standard Prophylactic DLI, Exercise Mobilized Therapeutic DLI, Standard Therapeutic DLI
Biological
Lead sponsor
University of Arizona
Other
Eligibility
Up to 65 Years
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 12, 2026 · Synced Sep 17, 2026, 9:13 AM EDT